Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.

NCT03970044 · Completed

Last updated 2026-05-28

This clinical trial is testing whether combining the medications exenatide and dapagliflozin can help manage blood sugar levels over 24 hours in adults with type 2 diabetes, as measured by a continuous glucose monitor.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 67 people

Who can join Ages 18–75 · all sexes

Timeline Started 2019-07 · est. completion 2021-06

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT03970044 ↗

Description as written by the study sponsor.

This is a Phase IV, single site, randomized, open-label, parallel study comparing BYDUREON-BCise plus FARXIGA to BYDUREON-BCise alone and FARXIGA alone in patients diagnosed with Type 2 Diabetes Mellitus (T2DM) on a stable dose of metformin alone.

Treatments tested

Exenatide 2 MG also known as Bydureon, Bydureon BCise, Byetta Drug

Glucagon-like peptide-1 receptor
Dapagliflozin 10 MG also known as Farxiga 10 MG Drug

sodium-glucose co-transporter 2 (SGLT2) inhibitor

Main thing measured	MAGE
Sponsor	Consano Clinical Research, LLC
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03970044 ↗